D-1352-2020 Class II Ongoing

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-1352-2020 was initiated by Amneal Pharmaceuticals Of New York, LLC on May 29, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Jul 1, 2020
Initiation Date
May 29, 2020
Voluntary/Mandated
Voluntary: Firm initiated

Product description

amneal Metformin Hydrochloride Extended-Release Tablets, USP, 500 mg, 1000 tablets bottles, Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 NDC 53746-0178-10

Reason for recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Distribution pattern

Nationwide

Code information

HF08618A 6/30/2020 HF08718A 6/30/2020 HF15418A 7/31/2020 HF15518A 7/31/2020 HH11818A 9/30/2020 HJ00818A 9/30/2020 HJ00918A 9/30/2020 HJ01018A 9/30/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1352-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1352-2020. Report a data issue: hello@regdatalab.com.